Laaksonen R, Ojala J P, Tikkanen M J, Himberg J J
Department of Clinical Pharmacology, University of Helsinki, Finland.
Eur J Clin Pharmacol. 1994;46(4):313-7. doi: 10.1007/BF00194398.
Serum ubiquinone levels were studied during long- and short-term treatment with 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors in 17 men with primary non-familial hypercholesterolaemia. The serum ubiquinone levels were determined after the patients had received simvastatin (20-40 mg per day) for 4.7 years, after a 4 week treatment pause and again after they had resumed treatment with lovastatin (20-40 mg per day) for 12 weeks. During the treatment pause the average serum ubiquinone levels increased by 32%; resumption of treatment caused a reduction of 25%. The changes in the levels of ubiquinone and serum total cholesterol as well as those of ubiquinone and low-density lipoprotein cholesterol were closely parallel. This suggested that changes in serum ubiquinone reflected changes in cholesterol-containing serum lipoproteins which could serve as carrier vehicles for ubiquinone. After long-term simvastatin treatment and after short-term lovastatin treatment, average serum ubiquinone levels (1.16 and 1.22 mg.l-1, respectively) were similar to that observed in a group of apparently healthy middle-aged men (1.16 mg.l-1).
对17名原发性非家族性高胆固醇血症男性患者在长期和短期使用3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂治疗期间的血清泛醌水平进行了研究。在患者接受辛伐他汀（每天20 - 40毫克）治疗4.7年后、经过4周的治疗中断以及再次接受洛伐他汀（每天20 - 40毫克）治疗12周后，测定血清泛醌水平。在治疗中断期间，血清泛醌平均水平升高了32%；恢复治疗导致其降低了25%。泛醌水平与血清总胆固醇水平的变化以及泛醌与低密度脂蛋白胆固醇水平的变化密切平行。这表明血清泛醌的变化反映了含胆固醇血清脂蛋白的变化，而这些脂蛋白可作为泛醌的载体。经过长期辛伐他汀治疗和短期洛伐他汀治疗后，血清泛醌平均水平（分别为1.16和1.22毫克·升⁻¹）与一组明显健康的中年男性（1.16毫克·升⁻¹）中观察到的水平相似。
